Evotec AG Earnings Call: Weak 2026, Pipeline Hopes
TipRanks (Thu, 13-Aug 8:19 PM ET)
Seeking Alpha News (Thu, 13-Aug 3:02 PM ET)
TipRanks (Thu, 13-Aug 6:28 AM ET)
RBC Capital Reaffirms Their Buy Rating on Evotec (0IRF)
TipRanks (Thu, 13-Aug 3:55 AM ET)
PRNewswire (Thu, 6-Aug 2:18 AM ET)
Business Wire (Mon, 3-Aug 8:32 AM ET)
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management
Business Wire (Thu, 23-Jul 3:00 AM ET)
PRNewswire (Mon, 13-Jul 3:44 PM ET)
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
PRNewswire (Tue, 30-Jun 2:18 AM ET)
Evotec Reports Results of the Annual General Meeting 2026
PRNewswire (Thu, 11-Jun 12:02 PM ET)
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Evotec Se - American Depositary Shares Each Representing 1/2 Of One Ordinary Share trades on the NASDAQ stock market under the symbol EVO.
As of August 13, 2026, EVO stock price declined to $2.02 with 26,007 million shares trading.
EVO has a beta of 2.98, meaning it tends to be more sensitive to market movements. EVO has a correlation of 0.28 to the broad based SPY ETF.
EVO has a market cap of $717.89 million. This is considered a Small Cap stock.
Last quarter Evotec Se - American Depositary Shares Each Representing 1/2 Of One Ordinary Share reported $183 million in Revenue and -$.40 earnings per share. This fell short of revenue expectation by $-14 million and missed earnings estimates by -$.48.
In the last 3 years, EVO traded as high as $12.40 and as low as $1.90.
EVO has underperformed the market in the last year with a price return of -47.0% while the SPY ETF gained +22.2%. EVO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -32.7% and +4.7%, respectively, while the SPY returned +5.6% and +6.6%, respectively.
EVO support price is $2.12 and resistance is $2.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVO shares will trade within this expected range on the day.